Ceribell to Participate in the 45th Annual TD Cowen Healthcare Conference

Rhea-AI Summary

Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnosis and management, has announced its participation in the 45th Annual TD Cowen Healthcare Conference. The company's CEO and Co-founder, Jane Chao, Ph.D., along with CFO Scott Blumberg, will engage in a fireside chat scheduled for March 3, 2025, at 6:50 AM PST / 9:50 AM EST.

Interested parties can access both live and archived versions of the presentation through the Investor Relations section of Ceribell's website at investors.ceribell.com.

News Market Reaction – CBLL

+0.82%

+0.82% Session move

In the trading session that priced this news, CBLL gained 0.82%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SUNNYVALE, Calif., Feb. 18, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that Jane Chao, Ph.D., CEO and Co-founder, and Scott Blumberg, CFO, will participate in a fireside chat at the upcoming 45^th Annual TD Cowen Health Care Conference. The fireside chat will take place on Monday, March 3, 2025, at 6:50 a.m. Pacific Standard Time / 9:50 a.m. Eastern Standard Time. 

Event: 45^th Annual TD Cowen Health Care Conference
Date: Monday, March 3, 2025
Time: 6:50 a.m. PST / 9:50 a.m. EST

A live and archived webcast of the presentation will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/. 

About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.

Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com

Media Contact
Corrie Rose
Press@ceribell.com

FAQ

When is Ceribell (CBLL) presenting at the TD Cowen Healthcare Conference 2025?

Ceribell (CBLL) will present at the TD Cowen Healthcare Conference on March 3, 2025, at 6:50 AM PST / 9:50 AM EST.

Who will represent Ceribell (CBLL) at the 2025 TD Cowen Healthcare Conference?

CEO and Co-founder Jane Chao, Ph.D., and CFO Scott Blumberg will represent Ceribell in a fireside chat at the conference.

How can investors watch Ceribell's (CBLL) presentation at the TD Cowen Healthcare Conference?

Investors can watch the live and archived webcast of the presentation through Ceribell's Investor Relations website at investors.ceribell.com.

What is the focus of Ceribell's (CBLL) medical technology business?

Ceribell focuses on transforming the diagnosis and management of patients with serious neurological conditions.